Brief: Promore Pharma Updates Its Strategy And Focuses On Scar Prevention

PMD Device Solutions AB

31/03/2021 06:14

March 31 (Reuters) - Promore Pharma AB  PROMO.ST :
    * PROMORE PHARMA UPDATES ITS STRATEGY AND FOCUSES ON SCAR
PREVENTION
    * EVELOPMENT OF DRUG CANDIDATE ENSEREPTIDE (PXL01) WILL
FOCUS ON
SCAR PREVENTION IN CONNECTION WITH SURGERY.
    * STRONG AND IMPROVED PATENT SITUATION IN USA AND THAT A
ROBUST
PRODUCTION PROCESS HAS BEEN ENSURED
    * CAPITAL REQUIREMENT IS CONSIDERABLY REDUCED AT SAME TIME
AS
ENSEREPTIDE CAN ADDRESS A SIGNIFICANTLY LARGER MARKET THAN
BEFORE
    * TO CARRY OUT A SMALLER PHASE II TRIAL IN SCAR PREVENTION
INSTEAD
OF A LARGE PHASE III TRIAL IN FLEXION SURGERY
    * HAS SUFFICIENT LIQUIDITY TO FINANCE ITS OPERATIONS
THROUGHOUT
2021 AND AIMS TO SECURE CAPITAL FOR FUTURE CLINICAL STUDIES
DURING CURRENT YEAR
    * ACTIVITIES DESCRIBED IN ENSEREPTIDE AND ROPOCAMPTIDE
PROJECTS
ARE EXPECTED TO BE COMPLETED BY FALL 2022 AT LATEST
    * ACTIVITIES DESCRIBED IN ENSEREPTIDE AND ROPOCAMPTIDE
PROJECTS
ARE EXPECTED TO BE COMPLETED BY FALL 2022 AT LATEST
    * TO CONDUCT TECHNICAL DEVELOPMENT OF ROPOCAMPTIDE DOSAGE
FORM TO
IMPROVE PRODUCT.
    * RESULT OF UPDATED STRATEGY IS THAT NEED FOR CAPITAL
DECREASES
SIGNIFICANTLY COMPARED WITH PREVIOUS OBJECTIVE OF FINANCING
PHASE III TRIAL FOR PXL01

Source text for Eikon:  ID:nMFN9WNK6w 
Further company coverage:  PROMO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 587696600;))